Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex

Prostate

Volumn 73, Issue 5, 2013, Pages 455-466

  Duan, Zhijian ^a   Zou, June X ^b   Yang, Ping ^a   Wang, Yuzhuo ^c,d   Borowsky, Alexander D ^a   Gao, Allen C ^a   Chen, Hong Wu ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

ANCCA; androgen; epigenetic regulators; EZH2; prostate development

Indexed keywords

ANDROGEN; HISTONE METHYLTRANSFERASE; KI 67 ANTIGEN; NUCLEAR RECEPTOR COACTIVATOR; PROTEIN ANCCA; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ANDROGEN THERAPY; ARTICLE; CASTRATION; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DEVELOPMENTAL STAGE; EMBRYO; EPITHELIUM; EPITHELIUM CELL; HUMAN; MALE; MESENCHYME; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE TUMOR; PROTEIN EXPRESSION; PUBERTY; REGULATORY MECHANISM;

ADENOSINE TRIPHOSPHATASES; ANDROGENS; ANIMALS; CELL LINE, TUMOR; CHROMATIN; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MULTIENZYME COMPLEXES; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASM TRANSPLANTATION; POLYCOMB REPRESSIVE COMPLEX 2; PREGNANCY; PROSTATE; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; SEXUAL MATURATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84875214218     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22587     Document Type: Article

References (57)

1. Shen MM, Abate-Shen C,. Molecular genetics of prostate cancer: New prospects for old challenges. Genes Dev 2010; 24 (18): 1967-2000.
2. Prins GS, Putz O,. Molecular signaling pathways that regulate prostate gland development. Differentiation 2008; 76 (6): 641-659.
3. Mirosevich J, Gao N, Matusik RJ,. Expression of Foxa transcription factors in the developing and adult murine prostate. Prostate 2005; 62 (4): 339-352.
4. Gao N, Ishii K, Mirosevich J, Kuwajima S, Oppenheimer SR, Roberts RL, Jiang M, Yu X, Shappell SB, Caprioli RM, Stoffel M, Hayward SW, Matusik RJ,. Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development 2005; 132 (15): 3431-3443.
5. Huang L, Pu Y, Hu WY, Birch L, Luccio-Camelo D, Yamaguchi T, Prins GS,. The role of Wnt5a in prostate gland development. Dev Biol 2009; 328 (2): 188-199.
6. Xu J, Wu RC, O'Malley BW,. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer 2009; 9 (9): 615-630.
7. Heemers HV, Tindall DJ,. Androgen receptor (AR) coregulators: A diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007; 28 (7): 778-808.
8. Chung AC, Zhou S, Liao L, Tien JC, Greenberg NM, Xu J,. Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice. Cancer Res 2007; 67 (12): 5965-5975.
9. Zou JX, Guo L, Revenko AS, Tepper CG, Gemo AT, Kung HJ, Chen HW,. Androgen-induced coactivator ANCCA mediates specific androgen receptor signaling in prostate cancer. Cancer Res 2009; 69 (8): 3339-3346.
10. Zou JX, Revenko AS, Li LB, Gemo AT, Chen HW,. ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification. Proc Natl Acad Sci USA 2007; 104 (46): 18067-18072.
11. Revenko AS, Kalashnikova EV, Gemo AT, Zou JX, Chen HW,. Chromatin loading of E2F-MLL complex by cancer-associated coregulator ANCCA via reading a specific histone mark. Mol Cell Biol 2010; 30 (22): 5260-5272.
12. Caron C, Lestrat C, Marsal S, Escoffier E, Curtet S, Virolle V, Barbry P, Debernardi A, Brambilla C, Brambilla E, Rousseaux S, Khochbin S,. Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers. Oncogene 2010; 29 (37): 5171-5181.
13. Ciro M, Prosperini E, Quarto M, Grazini U, Walfridsson J, McBlane F, Nucifero P, Pacchiana G, Capra M, Christensen J, Helin K,. ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res 2009; 69 (21): 8491-8498.
14. Varier RA, Timmers HT,. Histone lysine methylation and demethylation pathways in cancer. Biochim Biophys Acta 2011; 1815 (1): 75-89.
15. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM,. The Polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419 (6907): 624-629.
16. Chase A, Cross NC,. Aberrations of EZH2 in cancer. Clin Cancer Res 2011; 17 (9): 2613-2618.
17. Karanikolas BD, Figueiredo ML, Wu L,. Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines. Prostate 2010; 70 (6): 675-688.
18. Bracken AP, Kleine-Kohlbrecher D, Dietrich N, Pasini D, Gargiulo G, Beekman C, Theilgaard-Monch K, Minucci S, Porse BT, Marine JC, Hansen KH, Helin K,. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev 2007; 21 (5): 525-530.
19. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, Mehra R, Laxman B, Cao X, Kleer CG, Varambally S, Chinnaiyan AM,. Repression of E-cadherin by the Polycomb group protein EZH2 in cancer. Oncogene 2008; 27 (58): 7274-7284.
20. Cheng AS, Lau SS, Chen Y, Kondo Y, Li MS, Feng H, Ching AK, Cheung KF, Wong HK, Tong JH, Jin H, Choy KW, Yu J, To KF, Wong N, Huang TH, Sung JJ,. EZH2-mediated concordant repression of Wnt antagonists promotes beta-catenin-dependent hepatocarcinogenesis. Cancer Res 2011; 71 (11): 4028-4039.
21. Kotake Y, Cao R, Viatour P, Sage J, Zhang Y, Xiong Y,. pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene. Genes Dev 2007; 21 (1): 49-54.
22. Yang X, Karuturi RK, Sun F, Aau M, Yu K, Shao R, Miller LD, Tan PB, Yu Q,. CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS ONE 2009; 4 (4): e5011.
23. Wang L, Jin Q, Lee JE, Su IH, Ge K,. Histone H3K27 methyltransferase Ezh2 represses Wnt genes to facilitate adipogenesis. Proc Natl Acad Sci USA 2010; 107 (16): 7317-7322.
24. Boyer LA, Plath K, Zeitlinger J, Brambrink T, Medeiros LA, Lee TI, Levine SS, Wernig M, Tajonar A, Ray MK, Bell GW, Otte AP, Vidal M, Gifford DK, Young RA, Jaenisch R,. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 2006; 441 (7091): 349-353.
25. Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y, Cheng H, Laxman B, Vellaichamy A, Shankar S, Li Y, Dhanasekaran SM, Morey R, Barrette T, Lonigro RJ, Tomlins SA, Varambally S, Qin ZS, Chinnaiyan AM,. An integrated network of androgen receptor, Polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010; 17 (5): 443-454.
26. Lee ST, Li Z, Wu Z, Aau M, Guan P, Karuturi RK, Liou YC, Yu Q,. Context-specific regulation of NF-kappaB target gene expression by EZH2 in breast cancers. Mol Cell 2011; 43 (5): 798-810.
27. Shi B, Liang J, Yang X, Wang Y, Zhao Y, Wu H, Sun L, Zhang Y, Chen Y, Li R, Hong M, Shang Y,. Integration of estrogen and Wnt signaling circuits by the Polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol 2007; 27 (14): 5105-5119.
28. Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo AM,. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget 2011; 2 (9): 669-683.
29. Kunderfranco P, Mello-Grand M, Cangemi R, Pellini S, Mensah A, Albertini V, Malek A, Chiorino G, Catapano CV, Carbone GM,. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer. PLoS ONE 2010; 5 (5): e10547.
30. Neri F, Zippo A, Krepelova A, Cherubini A, Rocchigiani M, Oliviero S,. Myc regulates the transcription of the PRC2 gene to control the expression of developmental genes in embryonic stem cells. Mol Cell Biol 2012; 32 (4): 840-851.
31. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM,. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008; 322 (5908): 1695-1699.
32. Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, Watt K, Tam T, Yang YC, Banuelos CA, Williams DE, McEwan IJ, Wang Y, Sadar MD,. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010; 17 (6): 535-546.
33. Hu P, Chu GC, Zhu G, Yang H, Luthringer D, Prins G, Habib F, Wang Y, Wang R, Chung LW, Zhau HE,. Multiplexed quantum dot labeling of activated c-Met signaling in castration-resistant human prostate cancer. PLoS ONE 2011; 6 (12): e28670.
34. Wang Y, Hayward S, Cao M, Thayer K, Cunha G,. Cell differentiation lineage in the prostate. Differentiation 2001; 68 (4-5): 270-279.
35. Kalashnikova EV, Revenko AS, Gemo AT, Andrews NP, Tepper CG, Zou JX, Cardiff RD, Borowsky AD, Chen HW,. ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res 2010; 70 (22): 9402-9412.
36. Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, Rotter V,. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 2004; 23 (34): 5759-5769.
37. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, Sugimura Y,. The endocrinology and developmental biology of the prostate. Endocr Rev 1987; 8 (3): 338-362.
38. Wu X, Daniels G, Shapiro E, Xu K, Huang H, Li Y, Logan S, Greco MA, Peng Y, Monaco ME, Melamed J, Lepor H, Grishina I, Lee P,. LEF1 identifies androgen-independent epithelium in the developing prostate. Mol Endocrinol 2011; 25 (6): 1018-1026.
39. Hofman K, Swinnen JV, Verhoeven G, Heyns W,. E2F activity is biphasically regulated by androgens in LNCaP cells. Biochem Biophys Res Commun 2001; 283 (1): 97-101.
40. Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT,. EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 2007; 67 (5): 547-556.
41. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K,. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003; 22 (20): 5323-5335.
42. Tyagi S, Chabes AL, Wysocka J, Herr W,. E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyltransferases. Mol Cell 2007; 27 (1): 107-119.
43. Takeda S, Chen DY, Westergard TD, Fisher JK, Rubens JA, Sasagawa S, Kan JT, Korsmeyer SJ, Cheng EH, Hsieh JJ,. Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression. Genes Dev 2006; 20 (17): 2397-2409.
44. Marker PC,. Does prostate cancer co-opt the developmental program ? Differentiation 2008; 76 (6): 736-744.
45. Cunha GR, Ricke W, Thomson A, Marker PC, Risbridger G, Hayward SW, Wang YZ, Donjacour AA, Kurita T,. Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol 2004; 92 (4): 221-236.
46. Lai KP, Yamashita S, Vitkus S, Shyr CR, Yeh S, Chang C,. Suppressed prostate epithelial development with impaired branching morphogenesis in mice lacking stromal fibromuscular androgen receptor. Mol Endocrinol 2012; 26 (1): 52-66.
47. Yu S, Yeh CR, Niu Y, Chang HC, Tsai YC, Moses HL, Shyr CR, Chang C, Yeh S,. Altered prostate epithelial development in mice lacking the androgen receptor in stromal fibroblasts. Prostate 2012; 72 (4): 437-449.
48. Wu CT, Altuwaijri S, Ricke WA, Huang SP, Yeh S, Zhang C, Niu Y, Tsai MY, Chang C,. Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor. Proc Natl Acad Sci USA 2007; 104 (31): 12679-12684.
49. Memarzadeh S, Cai H, Janzen DM, Xin L, Lukacs R, Riedinger M, Zong Y, DeGendt K, Verhoeven G, Huang J, Witte ON,. Role of autonomous androgen receptor signaling in prostate cancer initiation is dichotomous and depends on the oncogenic signal. Proc Natl Acad Sci USA 2011; 108 (19): 7962-7967.
50. Vander Griend DJ, D'Antonio J, Gurel B, Antony L, Demarzo AM, Isaacs JT,. Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells. Prostate 2010; 70 (1): 90-99.
51. Ringrose L, Paro R,. Polycomb/Trithorax response elements and epigenetic memory of cell identity. Development 2007; 134 (2): 223-232.
52. Tsihlias J, Zhang W, Bhattacharya N, Flanagan M, Klotz L, Slingerland J,. Involvement of p27Kip1 in G1 arrest by high dose 5 alpha-dihydrotestosterone in LNCaP human prostate cancer cells. Oncogene 2000; 19 (5): 670-679.
53. Denmeade SR, Isaacs JT,. Bipolar androgen therapy: The rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer. Prostate 2010; 70 (14): 1600-1607.
54. Bohrer LR, Chen S, Hallstrom TC, Huang H,. Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: A potential mechanism of androgen-refractory progression of prostate cancer. Endocrinology 2010; 151 (11): 5136-5145.
55. Sonnenschein C, Olea N, Pasanen ME, Soto AM,. Negative controls of cell proliferation: Human prostate cancer cells and androgens. Cancer Res 1989; 49 (13): 3474-3481.
56. Chung CW, Witherington J,. Progress in the discovery of small-molecule inhibitors of bromodomain-histone interactions. J Biomol Screen 2011; 16 (10): 1170-1185.
57. Muller S, Filippakopoulos P, Knapp S,. Bromodomains as therapeutic targets. Expert Rev Mol Med 2011; 13: e29.